Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017)

Historic Liabilities from Discontinued Operations for Harvard Bioscience (HBIO) over the last 1 years, with Q4 2017 value amounting to $1.9 million.

  • Harvard Bioscience's Liabilities from Discontinued Operations changed N/A to $1.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2017, which is N/A changed from last year.
  • Per Harvard Bioscience's latest filing, its Liabilities from Discontinued Operations stood at $1.9 million for Q4 2017.
  • In the past 5 years, Harvard Bioscience's Liabilities from Discontinued Operations registered a high of $1.9 million during Q4 2017, and its lowest value of $1.9 million during Q4 2017.